These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29308539)

  • 1. Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
    van Steen SC; Woodward M; Chalmers J; Li Q; Marre M; Cooper ME; Hamet P; Mancia G; Colagiuri S; Williams B; Grobbee DE; DeVries JH;
    Diabetologia; 2018 Apr; 61(4):780-789. PubMed ID: 29308539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial.
    van Steen SC; Schrieks IC; Hoekstra JB; Lincoff AM; Tardif JC; Mellbin LG; Rydén L; Grobbee DE; DeVries JH;
    Eur J Prev Cardiol; 2017 May; 24(8):858-866. PubMed ID: 28186441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights from ADVANCE.
    Chalmers J; Kengne AP; Joshi R; Perkovic V; Patel A
    J Hypertens Suppl; 2007 Jun; 25(1):S23-30. PubMed ID: 17579315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADVANCE: breaking new ground in type 2 diabetes.
    Chalmers J; Perkovic V; Joshi R; Patel A
    J Hypertens Suppl; 2006 Aug; 24(5):S22-8. PubMed ID: 16936533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial.
    Chalmers J; Arima H; Woodward M; Mancia G; Poulter N; Hirakawa Y; Zoungas S; Patel A; Williams B; Harrap S
    Hypertension; 2014 Feb; 63(2):259-64. PubMed ID: 24324048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
    van der Leeuw J; Visseren FL; Woodward M; Zoungas S; Kengne AP; van der Graaf Y; Glasziou P; Hamet P; MacMahon S; Poulter N; Grobbee DE; Chalmers J
    Hypertension; 2015 Jan; 65(1):115-21. PubMed ID: 25312436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
    Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
    N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.
    Batty GD; Li Q; Czernichow S; Neal B; Zoungas S; Huxley R; Patel A; de Galan BE; Woodward M; Hamet P; Harrap SB; Poulter N; Chalmers J;
    J Am Coll Cardiol; 2010 Nov; 56(23):1908-13. PubMed ID: 21109113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial.
    Selvin E; Wang D; McEvoy JW; Juraschek SP; Lazo M; Hamet P; Cooper ME; Marre M; Williams B; Harrap S; Chalmers J; Woodward M
    Diabetes Obes Metab; 2019 Aug; 21(8):2017-2023. PubMed ID: 31050156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
    de Galan BE; Zoungas S; Chalmers J; Anderson C; Dufouil C; Pillai A; Cooper M; Grobbee DE; Hackett M; Hamet P; Heller SR; Lisheng L; MacMahon S; Mancia G; Neal B; Pan CY; Patel A; Poulter N; Travert F; Woodward M;
    Diabetologia; 2009 Nov; 52(11):2328-2336. PubMed ID: 19688336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation.
    J Hypertens Suppl; 2001 Nov; 19(4):S21-8. PubMed ID: 11848259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
    Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
    Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
    Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
    Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus.
    Rahman F; McEvoy JW; Ohkuma T; Marre M; Hamet P; Harrap S; Mancia G; Rodgers A; Selvin E; Williams B; Muntner P; Chalmers J; Woodward M
    Hypertension; 2019 Jun; 73(6):1291-1299. PubMed ID: 31030606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
    Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
    Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ADVANCE study: objectives, design and current status].
    Chalmers J
    Drugs; 2003; 63 Spec No 1():39-44. PubMed ID: 12708881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials.
    Waeber B
    J Hypertens Suppl; 2006 May; 24(3):S19-27. PubMed ID: 16723862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADVANCE: action in diabetes and vascular disease.
    Patel A; Chalmers J; Poulter N
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S27-32. PubMed ID: 16075030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
    van der Leeuw J; Visseren FL; Woodward M; van der Graaf Y; Grobbee DE; Harrap S; Heller S; Mancia G; Marre M; Poulter N; Zoungas S; Chalmers J
    Diabetologia; 2016 Dec; 59(12):2603-2612. PubMed ID: 27586250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The prevention of the hypertension related damage in type-2 diabetes: the first step of the ADVANCE trial].
    Nagy V
    Orv Hetil; 2008 Jan; 149(1):19-22. PubMed ID: 18089478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.